Essentially, during disease progression, a reduction in the number of cytotoxic CD8+ T cells and an increase in the atypical CD4+ T cell infiltrate takes place accompanied by a shift from an anti-tumor Th1 to a tumor-promoting Th2-type immune response [38] (Figure 1a–c). Here, CD4 is linked to neoplasm.